Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz Acetate for NAFLD with Hypertension
NCT05084404Phase 2Unknown
- Sponsor
- Yokohama City University
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of guanabenz in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by Yokohama City University. Status: unknown.
02
Drugs
guanabenz
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05084404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084404.